CINECA IRIS Institutional Research Information System

DE NICOLO', Amedeo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.136
EU - Europa 5.589
AS - Asia 5.467
Continente sconosciuto - Info sul continente non disponibili 817
SA - Sud America 813
AF - Africa 154
OC - Oceania 34
Totale 25.010
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.718
SG - Singapore 2.332
IT - Italia 1.780
CN - Cina 1.427
DK - Danimarca 580
VN - Vietnam 574
BR - Brasile 539
IE - Irlanda 483
FR - Francia 477
SE - Svezia 443
DE - Germania 362
AT - Austria 282
FI - Finlandia 268
GB - Regno Unito 248
IN - India 216
CA - Canada 207
HK - Hong Kong 176
UA - Ucraina 167
KR - Corea 162
BD - Bangladesh 115
NL - Olanda 98
JP - Giappone 92
CL - Cile 88
ID - Indonesia 84
AR - Argentina 73
MX - Messico 68
PL - Polonia 60
ES - Italia 58
IQ - Iraq 57
CZ - Repubblica Ceca 40
RU - Federazione Russa 39
ZA - Sudafrica 39
CH - Svizzera 38
BE - Belgio 36
JM - Giamaica 34
AU - Australia 32
CO - Colombia 27
TR - Turchia 27
EC - Ecuador 26
TH - Thailandia 26
CR - Costa Rica 25
EG - Egitto 25
RO - Romania 25
VE - Venezuela 25
PK - Pakistan 23
GR - Grecia 21
HR - Croazia 21
UZ - Uzbekistan 18
MA - Marocco 16
NI - Nicaragua 13
PY - Paraguay 13
TW - Taiwan 13
HN - Honduras 12
KE - Kenya 12
AE - Emirati Arabi Uniti 11
TT - Trinidad e Tobago 11
NG - Nigeria 10
PE - Perù 10
JO - Giordania 9
LT - Lituania 9
PH - Filippine 9
PT - Portogallo 9
SN - Senegal 9
DZ - Algeria 8
EU - Europa 8
GT - Guatemala 8
IL - Israele 8
MY - Malesia 8
PS - Palestinian Territory 8
SA - Arabia Saudita 8
TN - Tunisia 8
AZ - Azerbaigian 7
BB - Barbados 7
BY - Bielorussia 7
PR - Porto Rico 7
RS - Serbia 7
UY - Uruguay 7
KG - Kirghizistan 6
QA - Qatar 6
SV - El Salvador 6
GE - Georgia 5
KZ - Kazakistan 5
LV - Lettonia 5
NO - Norvegia 5
BO - Bolivia 4
BS - Bahamas 4
EE - Estonia 4
ET - Etiopia 4
KW - Kuwait 4
LB - Libano 4
NP - Nepal 4
CU - Cuba 3
DO - Repubblica Dominicana 3
IR - Iran 3
LK - Sri Lanka 3
MN - Mongolia 3
BF - Burkina Faso 2
BG - Bulgaria 2
BH - Bahrain 2
BW - Botswana 2
Totale 24.142
Salva come PNG Salva come JPEG
Città #
Singapore 1.328
Ann Arbor 1.314
Ashburn 1.138
Chandler 986
San Jose 695
Beijing 674
Santa Clara 641
Dublin 480
Fairfield 342
Torino 312
Houston 304
Woodbridge 253
Milan 231
Nyköping 221
Vienna 218
Dearborn 196
Villeurbanne 190
Turin 186
Wilmington 186
Los Angeles 165
Council Bluffs 160
Ho Chi Minh City 156
Columbus 149
Hong Kong 142
Medford 141
Princeton 133
The Dalles 130
Lauterbourg 129
Seattle 127
Dallas 125
Hanoi 120
New York 119
Cambridge 117
Rome 111
Hefei 106
Seoul 106
Fremont 102
Jacksonville 98
Redwood City 96
Buffalo 89
Munich 89
Helsinki 71
Boardman 66
Santiago 63
São Paulo 61
Tokyo 61
Jakarta 60
Toronto 59
Boston 54
Orem 53
Nuremberg 49
Dong Ket 43
Washington 43
Phoenix 42
Redondo Beach 42
Verona 42
Guangzhou 41
Shanghai 41
Warsaw 41
Burlington 40
Bengaluru 39
Pisa 39
Turku 39
Atlanta 36
Chicago 36
Frankfurt am Main 36
London 36
Nanjing 35
Hangzhou 34
Brussels 29
Mexico City 29
Naples 29
Da Nang 27
Brno 26
Mumbai 26
Bologna 25
San Diego 25
Baghdad 23
Lappeenranta 23
Philadelphia 23
Chennai 22
Montreal 22
Brooklyn 21
Manchester 21
Memphis 21
Rio de Janeiro 21
San José 21
Kingston 20
Norwalk 20
Amsterdam 19
Chengdu 19
Florence 19
Hebei 19
San Francisco 19
Silver Spring 19
Bari 18
Stockholm 18
Belo Horizonte 17
Düsseldorf 17
Haiphong 17
Totale 14.582
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 513
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 486
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 333
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 310
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 310
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 303
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 301
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 297
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 286
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 273
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study 271
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 261
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 253
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 251
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 240
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 233
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 233
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 232
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 229
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 228
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 227
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir 223
An UPLC MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in Peripheral Blood Mononuclear Cells 218
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension 215
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 212
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 211
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 210
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 210
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 210
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 210
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 210
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 208
Pharmacokinetic and pharmacogenetic analysis of tacrolimus in pediatric liver transplant patients in the early post-liver transplantation period 206
Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment? 204
Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis 201
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 201
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 196
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 195
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 195
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 194
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 192
Quantification of tacrolimus in PBMCs samples in pediatric liver transplant patients and correlation with tacrolimus whole blood concentration 191
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 191
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 189
Cannabinoids concentration variability in cannabis olive oil galenic preparations 189
A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring 189
Pharmacogenetics of ribavirin-induced anemia in HCV patients 186
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 182
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants 181
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 176
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 172
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients 171
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 171
Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma 167
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 163
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients 163
A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues 162
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 162
UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists' drugs in human plasma 160
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening 160
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 158
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 156
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 156
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 155
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 154
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 154
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples 153
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 152
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting 150
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 150
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration 150
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma 150
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 146
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 146
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 146
Analytical validation of a novel UHPLC-MS/MS method for 19 antibiotics quantification in plasma: Implementation in a LC-MS/MS Kit 145
UHPLC-MS/MS Method with On-line SPE to Quantify Tacrolimus and Everolimus in Peripheral Blood Mononuclear Cells: Application of “IS-normalized” Matrix Effect 145
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 145
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 145
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 143
A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients 142
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 140
Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients 140
Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy 139
A new UHPLC-MS/MS method for cannabinoids determination in human plasma: A clinical tool for therapeutic drug monitoring 138
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 138
Seasonal variation of antiretroviral drug exposure during the year: The experience of 10 years of therapeutic drug monitoring 137
First UHPLC MS/MS method coupled with automated on-line SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients 136
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 135
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 134
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 131
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV 130
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 130
Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections 129
Pharmacogenetic of voriconazole antifungal agent in pediatric patients 129
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 129
UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples 127
Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context 127
Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series 126
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells 125
Totale 19.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.653
article - articoli 0
book - libri 0
conference - conferenze 10.442
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.095
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.882 0 0 0 196 156 213 181 152 114 129 388 353
2022/20232.773 249 234 71 258 253 659 164 230 315 61 182 97
2023/20241.120 154 194 78 54 64 152 28 51 13 59 103 170
2024/20253.237 52 154 133 285 798 246 82 156 359 196 286 490
2025/20267.384 785 350 413 791 684 358 1.056 341 564 523 475 1.044
2026/20271.976 299 496 641 540 0 0 0 0 0 0 0 0
Totale 25.010